MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...

which evaluated the drug in patients with PAH Functional Class (FC) III or IV at high risk of mortality. Data from this study showed that treatment with Winrevair, when added to background PAH ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

Merck discussed this decision to stop the HYPERION study early with the U.S. Food and Drug Administration ... class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first ...

Merck discussed this decision to stop the HYPERION study early with the U.S. Food and Drug Administration (FDA ... improve WHO functional class (FC) and reduce the risk of clinical worsening events.